Skip to main content
. 2018 Mar 14;2018(1):2. doi: 10.21542/gcsp.2018.2

Figure 3. Hazard ratios for incident CV events in the JUPITER trial according to achieved concentrations of LDL-C and Hs-CRP after initiation of rosuvastatin therapy.

Figure 3.